AU2018237046B2 - Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy - Google Patents

Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy Download PDF

Info

Publication number
AU2018237046B2
AU2018237046B2 AU2018237046A AU2018237046A AU2018237046B2 AU 2018237046 B2 AU2018237046 B2 AU 2018237046B2 AU 2018237046 A AU2018237046 A AU 2018237046A AU 2018237046 A AU2018237046 A AU 2018237046A AU 2018237046 B2 AU2018237046 B2 AU 2018237046B2
Authority
AU
Australia
Prior art keywords
arg
ser
seq
gly
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018237046A
Other languages
English (en)
Other versions
AU2018237046A1 (en
Inventor
Alan Epstein
Peisheng Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theraccines Ltd
Original Assignee
Cancer Therapeutics Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Therapeutics Laboratories Inc filed Critical Cancer Therapeutics Laboratories Inc
Publication of AU2018237046A1 publication Critical patent/AU2018237046A1/en
Priority to AU2024259793A priority Critical patent/AU2024259793A1/en
Application granted granted Critical
Publication of AU2018237046B2 publication Critical patent/AU2018237046B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018237046A 2017-03-20 2018-03-19 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy Active AU2018237046B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024259793A AU2024259793A1 (en) 2017-03-20 2024-11-07 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762473554P 2017-03-20 2017-03-20
US62/473,554 2017-03-20
PCT/US2018/023123 WO2018175310A1 (en) 2017-03-20 2018-03-19 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024259793A Division AU2024259793A1 (en) 2017-03-20 2024-11-07 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Publications (2)

Publication Number Publication Date
AU2018237046A1 AU2018237046A1 (en) 2019-09-26
AU2018237046B2 true AU2018237046B2 (en) 2024-11-14

Family

ID=63584724

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018237046A Active AU2018237046B2 (en) 2017-03-20 2018-03-19 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
AU2024259793A Pending AU2024259793A1 (en) 2017-03-20 2024-11-07 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024259793A Pending AU2024259793A1 (en) 2017-03-20 2024-11-07 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Country Status (8)

Country Link
US (3) US11384157B2 (cg-RX-API-DMAC10.html)
EP (1) EP3601364A4 (cg-RX-API-DMAC10.html)
JP (3) JP7299209B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240148849A (cg-RX-API-DMAC10.html)
CN (2) CN110461878B (cg-RX-API-DMAC10.html)
AU (2) AU2018237046B2 (cg-RX-API-DMAC10.html)
CA (1) CA3056703A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018175310A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240148849A (ko) * 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
LU103248B1 (en) 2024-02-19 2025-08-19 Stratec Se Container handling device
WO2025194038A1 (en) * 2024-03-15 2025-09-18 Caris Science, Inc. Antibody compositions and methods for targeting extracellular nucleosome proteins
US20260027155A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
US9260517B2 (en) * 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
WO2015106290A1 (en) * 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Internalizing moieties
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody
US20180194831A1 (en) * 2015-07-10 2018-07-12 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR20240148849A (ko) 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체

Also Published As

Publication number Publication date
JP2025066768A (ja) 2025-04-23
JP2020511541A (ja) 2020-04-16
AU2018237046A1 (en) 2019-09-26
US20250215114A1 (en) 2025-07-03
JP7299209B2 (ja) 2023-06-27
CN110461878A (zh) 2019-11-15
KR20240148849A (ko) 2024-10-11
KR20190130604A (ko) 2019-11-22
US12258421B2 (en) 2025-03-25
CN110461878B (zh) 2022-12-09
CA3056703A1 (en) 2018-09-27
US20200157246A1 (en) 2020-05-21
US11384157B2 (en) 2022-07-12
AU2024259793A1 (en) 2025-01-02
KR102698752B1 (ko) 2024-08-26
JP7624478B2 (ja) 2025-01-30
WO2018175310A4 (en) 2018-11-22
JP2023126794A (ja) 2023-09-12
CN115947859A (zh) 2023-04-11
EP3601364A4 (en) 2021-01-06
WO2018175310A1 (en) 2018-09-27
EP3601364A1 (en) 2020-02-05
US20230027730A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US12258421B2 (en) Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
CN114409773B (zh) 针对新型冠状病毒的纳米抗体及其应用
US20240368264A1 (en) Anti-TSLP nanobodies and their applications
CN112552408B (zh) 靶向caix抗原的纳米抗体及其应用
CN111718415B (zh) 一种抗tigit纳米抗体及其应用
CN113214394B (zh) 抗il5纳米抗体及其应用
JP7737471B2 (ja) 抗ｂｃａｍ抗体又はその抗原結合フラグメント
CN116120450A (zh) 靶向人cd38分子的驼科纳米抗体制备和应用
HK1257189A1 (zh) 用於抑制癌症干细胞的组合物和方法
HK40069791B (en) Nano-antibody targeting caix antigen and application thereof
Li Streamlined development of fully human antibody fragments for immunopet imaging using phage display technology

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)